Moleculin Biotech, Inc. (MBRX) stock
MBRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.87−0.19 (-2.36%)
Close on Nov 13, 2026Market cap $8.23MP/E –Yield –
Moleculin Biotech enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Moleculin Biotech's enterprise value was $50.25M on Nov 11, 2026, against $263.26M a year earlier. Over the last 5 years it ranged from $32.37M to $987.84M, with a median of $263.26M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $50.25M | -59.6% |
| 2025 | Dec 31, 2025 | $124.37M | +34.2% |
| 2024 | Dec 31, 2024 | $92.66M | -81.0% |
| 2023 | Dec 29, 2023 | $487.18M | -12.5% |
| 2022 | Dec 30, 2022 | $556.49M | -43.7% |
| 2021 | Dec 31, 2021 | $987.84M | +1.7% |
| 2020 | Dec 31, 2020 | $971.79M | +18.3% |
| 2019 | Dec 31, 2019 | $821.42M | +49.3% |
| 2018 | Dec 31, 2018 | $550.06M | -28.2% |
| 2017 | Dec 29, 2017 | $765.77M | +40.9% |
| 2016 | Dec 30, 2016 | $543.51M | – |
See a number that looks wrong?